Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px
Document › Details

Biotie Therapies Corporation. (6/26/12). "Press Release: Biotie Announces Roche Has Decided to Not Exercise Its Rights to SYN120, a Novel 5-HT6 Antagonist for Cognitive Disorders".

Organisations Organisation Biotie Therapies Corporation
  Group Acorda Therapeutics (Group)
  Organisation 2 Roche (Group)
Products Product SYN120 (Biotie)
  Product 2 drug development
Person Person Veromaa, Timo (BioTie 1998– VP RnD promoted CEO 5/05 before Schering Oy before Collagen Corp)
     


Biotie announced today that it is retaining global development and commercialization rights to SYN120, following Roche's decision not to exercise its opt-in right due to strategic portfolio reasons. SYN120 is Biotie's novel selective 5-HT6 receptor antagonist that has recently successfully completed a Phase 1 program including a study using positron emission tomography (PET) imaging to determine appropriate dosing for Phase 2 development.

Timo Veromaa, Chief Executive Officer of Biotie, commented: "5-HT6 is a very promising, clinically-validated target in cognitive disorders and SYN120 represents a truly exciting and differentiated product for the treatment of Alzheimer's disease, schizophrenia and other conditions. A number of reputable companies have already expressed an interest in the compound and we are confident that we will find a high quality partner".

SYN120 has an extensive package of clinical and preclinical data and is ready to enter Phase 2. In March 2012, Biotie reported top-line data from a Phase 1 clinical study using PET imaging to determine the occupancy of the 5HT6 receptor in the brain following administration of SYN120. The study showed that target levels of receptor occupancy expected for efficacy can be achieved with SYN120 doses that are an order of magnitude lower than those that have previously been shown to be safe and well tolerated for up to two weeks in healthy older volunteers. As such SYN120 is expected to demonstrate efficacy with a very wide safety margin.

Turku, 26 June 2012

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900
e-mail: virve.nurmi@biotie.com

DISTRIBUTION
NASDAQ OMX Helsinki Ltd
Main Media
www.biotie.com


About SYN120

SYN120 is a potent and selective oral 5-HT6 receptor antagonist, exclusively targeting regions in the brain associated with memory function. SYN120 has been shown to enhance cognition in various preclinical models, and has completed single and multiple-ascending dose studies in Phase 1 and a PET imaging study to determine appropriate dosing for Phase 2 development. The compound was discovered at Roche and is being developed by Biotie under a licensing agreement.


About Biotie

Biotie is a specialized drug development company focused on the development of drugs for neurodegenerative and psychiatric disorders (e.g. Parkinson's disease, Alzheimer's disease and other cognitive disorders, alcohol and drug dependence (addiction) and post traumatic stress disorder), and inflammatory and fibrotic liver disease.The company has a strong and balanced development portfolio with several innovative small molecule and biological drug candidates at different stages of clinical development. Biotie's products address diseases with high unmet medical need and significant market potential. Biotie has a strategic collaboration with UCB Pharma S.A. covering tozadenant for Parkinson's disease. The Marketing Authorization Application for Biotie's most advanced product, SelincroTM (nalmefene) for alcohol dependence was filed in the EU by our partner H. Lundbeck A/S and was accepted for review by the European Medicines Agency in December 2011.Biotie shares are listed on NASDAQ OMX Helsinki Ltd.

   
Record changed: 2017-04-02

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Acorda Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px




» top